Total Clarity Wealth Management Inc. Acquires 228 Shares of Axon Enterprise, Inc $AXON

Total Clarity Wealth Management Inc. raised its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 22.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,255 shares of the biotechnology company’s stock after acquiring an additional 228 shares during the period. Total Clarity Wealth Management Inc.’s holdings in Axon Enterprise were worth $1,039,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in AXON. Jennison Associates LLC boosted its stake in shares of Axon Enterprise by 23,203.7% in the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock valued at $322,961,000 after buying an additional 611,418 shares during the period. Nuveen LLC bought a new stake in Axon Enterprise during the first quarter worth $264,796,000. McElhenny Sheffield Capital Management LLC bought a new stake in Axon Enterprise during the second quarter worth $255,833,000. Westfield Capital Management Co. LP lifted its stake in Axon Enterprise by 29.8% during the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after purchasing an additional 212,931 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Axon Enterprise by 2.2% during the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after purchasing an additional 185,571 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

AXON has been the subject of a number of recent research reports. Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 2nd. Needham & Company LLC reissued a “buy” rating and set a $870.00 price objective on shares of Axon Enterprise in a research report on Wednesday, September 24th. UBS Group reissued a “neutral” rating and set a $840.00 price objective (up previously from $820.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Wolfe Research initiated coverage on shares of Axon Enterprise in a research report on Monday, July 7th. They set an “outperform” rating on the stock. Finally, Morgan Stanley set a $885.00 price target on shares of Axon Enterprise and gave the company an “overweight” rating in a research report on Friday, July 11th. Fourteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $841.64.

Axon Enterprise Stock Down 4.2%

Shares of NASDAQ:AXON opened at $703.03 on Monday. The firm has a fifty day moving average price of $755.57 and a two-hundred day moving average price of $714.84. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. Axon Enterprise, Inc has a one year low of $422.38 and a one year high of $885.91. The company has a market cap of $55.19 billion, a price-to-earnings ratio of 173.59, a PEG ratio of 27.30 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating the consensus estimate of $1.54 by $0.58. The firm had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business’s quarterly revenue was up 32.6% compared to the same quarter last year. During the same period last year, the firm earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. Analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Activity

In other news, Director Hadi Partovi acquired 1,358 shares of the stock in a transaction dated Wednesday, August 13th. The stock was purchased at an average cost of $740.00 per share, with a total value of $1,004,920.00. Following the completion of the purchase, the director owned 237,938 shares in the company, valued at approximately $176,074,120. The trade was a 0.57% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jeffrey C. Kunins sold 7,891 shares of the company’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $750.10, for a total transaction of $5,919,039.10. Following the transaction, the insider directly owned 144,538 shares of the company’s stock, valued at approximately $108,417,953.80. This trade represents a 5.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 59,932 shares of company stock valued at $45,115,616. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.